Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548 in Healthy Adult Subjects
Conditions
Interventions
VX-548
Locations
1
United States
ICON Salt Lake City
Salt Lake City, Utah, United States
Start Date
July 13, 2022
Primary Completion Date
September 17, 2022
Completion Date
September 17, 2022
Last Updated
March 20, 2024
NCT06346132
NCT07482709
NCT07351968
NCT06946290
NCT07041736
NCT06528288
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions